natgillin/translations-raw huggingface dataset:
In subjects with normal renal and hepatic function receiving concomitant administration of potent CYP3A4 inhibitors, the maximum daily dose of TOVIAZ should be 4 mg once daily (see section 4.5).
Za bolnike z normalnim delovanjem ledvic in jeter, ki sočasno prejemajo močne zaviralce CYP3A4, znaša največji dnevni odmerek zdravila TOVIAZ 4 mg enkrat na dan (glejte poglavje 4.5).
In subjects with renal impairment, renal clearance of single doses of zonisamide was positively correlated with creatinine clearance.
Pri bolnikih z ledvično okvaro ledvični očistek enkratnega odmerka zonisamida pozitivno korelira z očistkom kreatinina.
In subjects with severe hepatic impairment (Child-Pugh score of 10-13), a reduced dose of fosamprenavir 300 mg twice daily with a reduced dosing frequency of ritonavir 100 mg once daily delivered 19% lower plasma amprenavir Cmax, 23% lower AUC(0-12), and 38% lower C12 values, but similar unbound plasma amprenavir C12 values than achieved in subjects with normal hepatic function receiving the standard fosamprenavir with ritonavir 700 mg / 100 mg twice daily regimen.
Z manjšim odmerkom fosamprenavirja 300 mg dvakrat na dan in manj pogosto uporabo ritonavirja 100 mg enkrat na dan je bila pri osebah s hudo okvaro jeter (ocena po Child-Pughu 10-13) dosežena 19 % manjša Cmax amprenavirja v plazmi, 23 % manjša AUC(0-12) in 38 % manjša C12, a podobna C12 nevezanega plazemskega amprenavirja kot pri osebah z normalnim delovanjem jeter.
In subjects with severe renal impairment (ClCR ≤ 24 ml/min), plasma concentrations were 2.3 times the levels in healthy subjects (see section 4.2 and 4.4).
Pri osebah s hudo ledvično okvaro (ClCR ≤-24 ml/min) so bile plazemske koncentracije 2,3-krat višje kot pri zdravih osebah (glejte poglavji 4.2 in 4.4).
In subjects with severe renal impairment (creatinine clearance 10–30 ml/min), a 1.3- to 1.8-fold increase in ranolazine exposure was estimated.
Pri osebah s hudo ledvično okvaro (kreatininski očistek 10–30 ml/min) so ocenili, da je povečanje izpostavljenosti ranolazinu 1,3- do 1,8- krat večje.
In subjects with severe renal impairment (estimated creatinine clearance < 30 ml/min), varenicline exposure was increased 2.1-fold.
Pri preiskovancih s hudo okvaro ledvic (ocenjeni očistek kreatinina < 30 ml/min) je bila izpostavljenost vareniklinu 2,1-krat večja.
In subjects with severe renal impairment (mean estimated CLcr =
Pri ljudeh s hudo ledvično okvaro (ocenjeno povprečje
In subjects with severe renal impairment (mean estimated CLcr = 21.2 mL/min), dose-adjusted mean AUC0-24h was increased by 110% compared to healthy volunteers.
Pri ljudeh s hudo ledvično okvaro (ocenjeno povprečje CLcr = 21,2 ml/min) se je povprečna vrednost AUC
In subjects with severe renal impairment (mean estimated CLcr = 21.2 mL/min), dose-adjusted mean AUC0-24h was increased by 110% compared to healthy volunteers.
Pri ljudeh s hudo ledvično okvaro (ocenjeno povprečje CLcr = 21,2 ml/min) se je povprečna vrednost AUC glede na odmerek povečala za 110 % v primerjavi
In subjects with severe renal impairment (n=5) increase of exposure was 2.2-fold for Cmax and 3.7-fold for AUC.
Pri bolnikih s hudo okvaro delovanja ledvic (n=5) se je Cmax ob izpostavitvi povečala za 2,2-krat in AUC za 3,7-krat.
In subjects with the highest degree of renal impairment inhibition of total CA activity was greater although it was inferior to 90% at steady-state.
Pri preiskovancih z največjo stopnjo ledvične okvare je bila inhibicija celotne aktivnosti CA večja, četudi je bila nižja od 90% v stanju dinamičnega ravnovesja.
In subjects with type 1 or type 2 diabetes, inhaled human insulin has a faster onset of glucose lowering effect in the early hours after dosing when compared with subcutaneously administered fast- acting human insulin.
Pri bolnikih z diabetesom tipa 1 ali tipa 2 ima humani insulin za inhaliranje hitrejši nastop učinka glede zniževanja glukoze v prvih urah po odmerku kot subkutano injicirani hitrodelujoči humani insulin.
In subjects without clinical symptoms of hepatic injury or jaundice, reinitiation of ambrisentan may be considered following resolution of hepatic enzyme abnormalities.
Pri osebah brez kliničnih simptomov okvare jeter ali zlatenice pride ponovna uvedba ambrisentana v poštev, ko nepravilnosti jetrnih encimov minejo.
In subjects ≥ 65 years of age, adverse reactions of volume depletion, most commonly reported as hypotension, were reported in 1.7% and 0.8% of dapagliflozin-treated subjects and placebo-treated subjects, respectively (see section 4.4).
Pri osebah, starih ≥ 65 let, so o pomanjkanju volumna kot neželenemu učinku, najpogosteje poročali kot o hipotenziji in jo zabeležili pri 1,7 % oseb, ki so prejemale dapagliflozin in pri 0,8 % oseb, ki so prejemale placebo (glejte poglavje 4.4).
In subjects ≥ 65 years of age, adverse reactions related to renal impairment or failure were reported in 7.7% of subjects treated with dapagliflozin and 3.8% of subjects treated with placebo (see section 4.4).
Pri preiskovancih, starih 65 let ali več, so neželene učinke, povezane z okvaro ali odpovedjo ledvic, zabeležili pri 7,7 % tistih, ki so prejemali dapagliflozin, in pri 3,8 % tistih, ki so prejemali placebo (glejte poglavje 4.4).
In subsequent doses, mean maximum observed plasma concentrations ranged from 67 to 106 ng/ml for the 1.0 mg/m2 dose and 89 to 120 ng/ml for the 1.3 mg/m2 dose.
Pri ponovljenih odmerkih so bile povprečne vrednosti najvišjih plazemskih koncentracij v razponu 67 do 106 ng/ml pri odmerku 1,0 mg/m2 in 89 do 120 ng/ml pri odmerku 1,3 mg/m2.
In subsequent required conditional increases, the dose should be increased by 50% (increasing the dose volume to 1.5 times the volume administered in the previous month) up to a maximum dose of the veterinary medicinal product of 0.2 ml/kg current bodyweight.
Pri naslednjih pogojnih povečanjih odmerka se le-ta poveča za 50 % (odmerek zdravila se poveča za 1,5 odmerka, ki se je dajal prejšnji mesec) do maksimalnega odmerka 0,2ml/kg trenutne telesne mase.
In subsequent studies, in male paediatric patients above the age of 7, a reduction in pain was observed after 9 and 12 months of Replagal therapy compared to pre- treatment baseline.
V nadaljnjih študijah pri moških pediatričnih bolnikih , starejših od 7 let, so zmanjšanje bolečine opazili po 9 in 12 mesecih zdravljenja z zdravilom Replagal, v primerjavi z izhodiščnimi vrednostmi.
In such a circumstance, the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.
V takih okoliščinah je treba razmisliti o uporabi podpornih ukrepov skupaj z dajanjem specifičnega zdravila proti Clostridium difficile.
In such cases a coagulation test (see sections 4.4 and 5.1) may help to determine whether haemostasis is still impaired.
V teh primerih lahko s koagulacijskim testom (glejte poglavji 4.4 in 5.1) preverimo, ali je hemostaza še okvarjena.
In such cases supportive treatment may be necessary.
V teh primerih je potrebno dodatno podporno zdravljenje.
In such cases topical treatments are recommended, but mouthwashes containing alcohol, hydrogen peroxide, iodine and thyme derivatives should be avoided as they may exacerbate the condition.
V takih primerih je priporočeno lokalno zdravljenje, pri čemer se je treba izogibati raztopinam za izpiranje ust, ki vsebujejo alkohol, vodikov peroksid, jod ali izvlečke timijana, ker bi lahko poslabšale stanje.
In such cases topical treatments are recommended, but mouthwashes containing alcohol, peroxide, iodine and thyme derivatives should be avoided as they may exacerbate the condition.
V takih primerih je priporočeno lokalno zdravljenje, pri čemer se je treba izogibati raztopinam za izpiranje ust, ki vsebujejo alkohol, peroksid, jod ali izvlečke timijana, ker bi lahko poslabšale stanje.
In such cases treatment with antihistamines i.v. should be considered.
V takšnih primerih je treba razmisliti o zdravljenju z intravenskimi antihistaminiki.
In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age.
V primerih, kjer lahko pričakujemo maternalna protitelesa, je morebiti potrebno še tretje injiciranje v starosti 15 tednov.
In such cases, a new cartridge yielding a uniform suspension must be used.
V takšnem primeru je treba uporabiti nov vložek, ki da enakomerno suspenzijo.
In such cases, a new pen yielding a uniform suspension must be used.
V takšnem primeru je treba uporabiti nov injekcijski peresnik, ki da enakomerno suspenzijo.
In such cases, a specialised haemophilia centre should be contacted.
V takšnih primerih se je treba obrniti na specializirani center za hemofilijo.
In such cases, an appropriate symptomatic treatment should be provided.
V teh primerih je potrebno ustrezno simptomatično zdravljenje.
In such cases, death has been attributed to intra-vascular administration of the product or anaphylaxis.
V takih primerih je bila smrt posledica intravaskularnega dajanja zdravila ali anafilaktične reakcije.
In such cases, it is recommended that a specialised haemophilia centre be contacted.
Priporočamo, da se v takih primerih obrnete na center za hemofilijo.
In such cases, it is recommended that a specialised haemophilia centre be contacted.
V takih primerih priporočamo, da se obrnete na specializirani center za hemofilijo.
In such cases, it is recommended that a specialised haemophilia centre be contacted.
V takih primerih se priporoča posvet z zdravstvenim osebjem, specializiranim za obravnavo hemofilije.
In such cases, it is recommended that a specialised haemophilia centre be contacted.
V takih primerih se priporoča posvetovanje z zdravstvenim osebjem, specializiranim za obravnavo hemofilije.
In such cases, it is recommended that a specialised haemophilia centre be contacted.
V takšnih primerih je priporočljivo, da stopite v stik s specializiranim centrom za hemofilijo.
In such cases, it is recommended to discontinue treatment with Raptiva.
V teh primerih je priporočljivo prekiniti zdravljenje z Raptivo.
In such cases, patients should refrain from driving cars and using machines.
V takšnih primerih bolniki ne smejo voziti ali upravljati s stroji.
In such cases, the side effects may be more intense).
V takšnih primerih so učinki lahko močnejši.).
In such cases, the starting dose should be 150 mg every other day (see sections 4.2 and 5.2).
V takih primerih mora biti začetni odmerek 150 mg vsak drugi dan (glejte poglavji 4.2 in 5.2).
In such cases, the starting dose should be 150 mg every other day.
V takih primerih naj bo začetni odmerek 150 mg vsak drugi dan.
In such cases, the starting dose should be as above recommended, but administered every other day.
V takih primerih naj bo začetni odmerek 150 mg vsak drugi dan.
In such cases, the Western blot method is negative.
V takšnih primerjih je metoda Western blot negativna.
In such circumstance, the discontinuation of dalbavancin and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.
V takšnih okoliščinah je treba razmisliti o prekinitvi zdravljenja z dalbavancinom in uvesti podporne ukrepe skupaj z jemanjem posebnega zdravila proti bakteriji Clostridium difficile.
In such circumstances Lonquex should be discontinued at the discretion of the physician and appropriate treatment given.
V takih okoliščinah je treba uporabo zdravila Lonquex po presoji zdravnika prekiniti in bolnika ustrezno zdraviti.
In such circumstances Neulasta should be discontinued at the discretion of the physician and the appropriate treatment given (see section 4.8).
V takih primerih je treba zdravilo Neulasta po presoji zdravnika prenehati dajati in poskrbeti za ustrezno zdravljenje (glejte poglavje 4.8).
In such circumstances, Raptiva should be discontinued.
V takem primeru moramo zdravljenje z Raptivo prekiniti.
In such circumstances, the discontinuation of therapy with ceftolozane/tazobactam and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.
V takšnih primerih je treba razmisliti o prenehanju zdravljenja s ceftolozanom/tazobaktamom in o uporabi podpornih ukrepov skupaj s specifičnim zdravljenjem okužbe s Clostridium difficile.
In such instances, instructions for antibody testing should be followed.
V tovrstnih primerih sledite navodilom za testiranje protiteles.
In such patients, treatment with Gilenya should be considered only if the anticipated benefits outweigh the potential risks.
Pri takih bolniki lahko pride zdravljenje z zdravilom Gilenya v poštev samo v primeru, da pričakovane koristi zdravljenja presegajo potencialna tveganja.
In such situations, the management of your diabetes may require a lot of care and you may need to seek advice from your doctor or nurse.
V takih primerih bo urejanje vaše sladkorne bolezni zahtevalo veliko natančnost in se boste morali za nasvet obrniti na svojega zdravnika ali medicinsko sestro.
In such situations, your surgeon will be informed and might have to select an alternative treatment for you.
V teh primerih vas bo vaš kirurg o tem obvestil in morda za vas izbral drugo zdravljenje.
In summary, everolimus is a highly effective therapy for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signalling and, consequently, cell size and myelination.
Povzamemo lahko, da je everolimus zelo učinkovito zdravilo za ta model nevronov s tuberozno sklerozo, v katerem je koristi očitno mogoče pripisati delovanju na kompleks mTORC1 in Akt signaliziranje ter posledično na velikost celic in mielinizacijo.
In summary, the combination of erlotinib with proton pump inhibitors should be avoided.
Kombinaciji erlotiniba in zaviralca protonske črpalke se je treba izogibati.
In summary, these studies suggest that low dose radioiodine plus thyrotropin alpha is an effective treatment (with reduced radiation exposure) and Thyrogen was non-inferior to thyroid hormone withdrawal for pre-therapeutic stimulation in combination with radioiodine for post-surgical ablation of thyroid remnant tissue.
Skratka, ti dve študiji kažeta, da je radioaktivnega joda skupaj s tirotropinom alfa učinkovito zdravljenje (z zmanjšano izpostavljenostjo radioaktivnosti) in da zdravilo Thyrogen ni bilo slabše kot odstranitev tiroidnega hormona za predterapevtsko stimulacijo v kombinaciji z radioaktivnim jodom za pooperacijsko ablacijo preostalega tiroidnega tkiva.
In supportive analyses, positive treatment effect has been observed in all subgroups with the exception of the subgroup of patients with ileum as primary site of tumour origin (Ileum: HR=1.22 [95% CI: 0.56 to 2.65]; Non-ileum: HR=0.34 [95% CI: 0.22 to 0.54]; Lung: HR=0.43 [95% CI: 0.24 to 0.79]) (see Figure 4).
V okviru podporne analize so opažali pozitivne učinke zdravljenja v vseh podskupinah razen v podskupini bolnikov, pri katerih je bilo primarno mesto izvora tumorja ileum (ileum: razmerje tveganj HR=1,22 [95-odstotni IZ: 0,56 do 2,65]; izven ileuma: HR=0,34 [95-odstotni IZ: 0,22 do 0,54]; pljuča: HR=0,43 [95-odstotni IZ: 0,24 do 0,79]) (glejte sliko 4).
In surgery studies in which parecoxib was administered pre-operatively, no evidence of pharmacodynamic interaction was observed in patients receiving parecoxib and the inhalation anaesthetic agents nitrous oxide and isoflurane (see section 5.1).
V kirurških študijah, v katerih so parekoksib uporabili pred operacijo, pri bolnikih, ki so dobivali parekoksib in inhalacijska anestetika dušikov oksid in izofluran, niso ugotovili nobenih farmakodinamičnih interakcij (glejte poglavje 5.1).
In systemic juvenile idiopathic arthritis, RoActemra given by infusion has been compared with placebo in one main study involving 112 children who had inadequate responses to NSAID and systemic corticosteroid treatment.
Zdravilo RoActemra, ki je bilo dajano z infundiranjem, so pri sistemskem juvenilnem idiopatskem artritisu primerjali s placebom v eni glavni študiji, ki je vključevala 112 otrok z nezadostnimi odzivi na nesteroidna protivnetna zdravila (NSAID) in sistemsko zdravljenje s kortikosteroidi.
In systemic juvenile idiopathic arthritis, RoActemra is given as a 1-hour infusion once every two weeks at a dose of 8 mg per kilogram body weight in children weighing 30 kg or more, or 12 mg per kilogram body weight in children weighing less than 30 kg.
Zdravilo RoActemra se pri sistemskem juvenilnem idiopatskem artritisu daje kot enourna infuzija vsaka dva tedna v 8-miligramskem odmerku na kilogram telesne mase pri otrocih, ki tehtajo 30 kg ali več, ali v 12-miligramskem odmerku na kilogram telesne mase pri otrocih, ki tehtajo manj kot 30 kg.
In systemic sclerosis with digital ulcers, Tracleer was more effective at reducing the development of new digital ulcers than placebo.
Pri sistemski sklerozi z razjedami prstov je bilo zdravilo Tracleer pri zmanjševanju razvoja novih razjed prstov učinkovitejše od placeba.
In systemic sclerosis with digital ulcers, two studies have compared Stayveer with placebo in a total of 312 adults.
Koristi zdravila Stayveer pri sistemski sklerozi z razjedami prstov so proučevali v dveh študijah s skupno 312 odraslimi, v katerih so zdravilo primerjali s placebom.
In systemic sclerosis with digital ulcers, two studies have compared Tracleer film-coated tablets with placebo in a total of 312 adults.
Pri sistemski sklerozi z razjedami prstov sta bili izvedeni dve študiji, v katerih so filmsko obložene tablete zdravila Tracleer primerjali s placebom pri skupno 312 bolnikih.
In T-ALL the abnormal cells are mainly in the blood and bone marrow, and in T-LBL they are mainly in the lymphatic system (lymph nodes or thymus gland).
Pri T-ALL so nenormalne celice prisotne predvsem v krvi in kostnem mozgu, pri T-LBL pa v limfatičnem sistemu (bezgavkah ali timusu).
In Table 1, adverse reactions are listed by organ class.
V Preglednici 1 so neželeni učinki našteti po organskih sistemih.
In Table 4 the efficacy results of patients undergoing percutaneous coronary intervention (PCI) are presented.
V preglednici 4 so prikazani izsledki glede učinkovitosti pri bolnikih po perkutanem koronarnem posegu.
In Tables 1 to 5, numbers will be provided for events received during the reporting period and cumulatively.
V preglednicah 1 do 5, bodo na voljo števila za dogodke, prejete med obdobjem poročanja in kumulativno.
In target animal safety studies, subcutaneous administration was generally well tolerated.
Psi na splošno zdravilo, dano subkutano, dobro prenašajo.
In TAUSSIG, long-term use of Repatha demonstrated a sustained treatment effect as evidenced by reduction of LDL-C of approximately 20% to 30% in patients with homozygous familial hypercholesterolaemia not on apheresis and approximately 15% to 25% in patients with homozygous familial hypercholesterolaemia on apheresis (table 7).
V študiji TAUSSIG je dolgotrajna uporaba zdravila Repatha pokazala trajen terapevtski učinek, kot je pokazalo znižanje LDL-H za približno 20 do 30 % pri bolnikih s homozigotno družinsko hiperholesterolemijo, ki niso bili na aferezi, in približno 15 do 25 % pri bolnikih s homozigotno družinsko hiperholesterolemijo, ki so bili na aferezi (tabela 7).
In Taxespira 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml and 160 mg/8 ml vials the concentration of docetaxel is 20 mg/ ml.
V vialah zdravila Taxespira20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml in 160 mg/8 ml je koncentracija docetaksela 20 mg/ ml.
In Taxespira 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml and 160 mg/8 ml vials the concentration of docetaxel is 20 mg/ml.
V vialah zdravila Taxespira20 mg/ 1ml, 80 mg/4 ml, 120 mg /6 ml, 140 mg/7 ml in 160 mg/8 ml koncentracija dosetaksela znaša 20 mg/ml.
In TAXOTERE 160 mg/8 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo Taxotere 160 mg/8 ml, je koncentracija docetaksela 20 mg/ml.
In TAXOTERE 20 mg/1 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo Taxotere 20 mg/1 ml, je koncentracija docetaksela 20 mg/ml.
In TAXOTERE 80 mg /4 ml vial the concentration of docetaxel is 20 mg/ml.
V zdravilu TAXOTERE 80 mg/4 ml vialah je koncentracija docetaksela 20 mg/ml.
In TAXOTERE 80 mg/4 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo Taxotere 80 mg/4 ml, je koncentracija docetaksela 20 mg/ml.
In terms of reproductive development, growth and neurological development there were no propranolol-related effects or toxicologically significant findings at 40 mg/kg/day, correlating to safety margins of 1.2 in females and 2.9 in males, based on mean propranolol exposures on PND 21.
V zvezi z reproduktivnim razvojem, rastjo in nevrološkim razvojem ni bilo nobenih učinkov, povezanih z propranololom, ali toksikološko pomembnih ugotovitev pri 40 mg/kg/dan, kar ustreza varnostni meji 1,2 pri samicah in 2,9 pri samcih, na osnovi povprečne izpostavljenosti propranololu na PND 21.
In terms of safety, Enzepi’s side effects are comparable to other marketed products.
Z vidika varnosti so neželeni učinki zdravila Enzepi primerljivi z neželenimi učinki drugih zdravil na trgu.
In terms of safety, the side effects were considered acceptable and manageable with appropriate measures.
Kar zadeva varnost, se neželeni učinki štejejo za sprejemljive in jih je mogoče obvladati z ustreznimi ukrepi.
In terms of safety, there was a higher overall incidence of Grade 3-5 AEs in study E3200 relative to study ML18147.
Kar se tiče varnosti, je bila v študiji E3200 celokupno večja incidenca neželenih dogodkov stopnje 3–5 glede na študijo ML18147.
In terms of safety, Zytiga is well tolerated and its risks are considered manageable.
Z vidika varnosti bolniki zdravilo Zytiga dobro prenašajo, z njim povezana tveganja pa so obvladljiva.
In TESLASCAN, the manganese is bound to another chemical in a ‘chelate’.
Mangan v zdravilu TESLACAN je vezan z drugo kemično spojino v t.i. „kelat“.
In that case hCG should be withheld and pregnancy should be avoided in order to prevent multiple gestations.
V tem primeru je treba zdravljenje s hCG opustiti in poskrbeti, da ženska ne zanosi, da ne pride do večplodne nosečnosti.
In that case infusion sets with minimal priming space should be used (i.e.
V teh primerih je treba uporabiti komplete za infundiranje z najmanjšim možnim lastnim volumnom (tj.
In that case the needle should be attached without screwing.
V tem primeru je treba iglo namestiti brez privijanja.
In that study, sensitivity was 43.1%, specificity was 100%.
V tisti študiji je bila senzitivnost 43,1 % in specifičnost 100 %.
In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs.
V preskušanju PRoFESS (Prevention Regimen For Effectively avoiding Second Strokes) se je pri bolnikih, starih 50 let in starejših, ki so pred kratkim doživeli možgansko kap, med jemanjem telmisartana povečala pojavnost sepse, in sicer pri 0,70 % v primerjavi z 0,49 % pri bolnikih, zdravljenih s placebom [RR 1,43 (95-odstotni interval zaupanja 1,00 do 2,06)].
In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs.
V preskušanju PRoFESS (Prevention Regimen For Effectively avoiding Second Strokes) se je pri bolnikih, starih 50 let in starejših, ki so pred kratkim doživeli možgansko kap, med jemanjem telmisartana povečala pojavnost sepse, in sicer pri 0,70 % v primerjavi z 0,49 % pri zdravljenih s placebom [RR 1,43 (95-odstotni interval zaupanja 1,00 do 2,06)].
In the 1- to 24 mg/kg cohorts, peak serum concentrations (Cmax) after the first dose increased in approximate proportion to dose and volume of distribution was consistent with initial distribution into the plasma compartment.
V kohorti bolnikov, ki so prejemali odmerke od 1 do 24 mg/kg, je vrednost najvišje koncentracije v serumu (Cmax) po prvem odmerku naraščala približno sorazmerno z velikostjo odmerka, volumen porazdelitve pa je bil skladen z začetno porazdelitvijo v predelek plazme.